Depressive Disorder

Article

Does Brintellix Bring Anything New?

After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?

Fire in the Mind: The Depression-Inflammation Connection

We have all bumped up against the limits of the current model of antidepressant treatments for depression: the patient who comes in with a laundry list of failed medication trials, or a number of other complaints depicting a portrait of malaise—aches, pains, anhedonia, fatigue, brain fog, digestive woes—that don’t really respond to currently available agents. What if shifting our thinking about underlying causes might hold the answer to treatment of these individuals?

Deplin: Is it Just Folate by Another Name?

The Carlat Psychiatry Report

Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.

Research Update

NSAIDs May be Effective for Depression

Inflammation is hot, both literally and figuratively. The medical literature is replete with studies implicating inflammation as a possible root cause of diseases as varied as heart disease, cancer, Alzheimer’s disease, depression and, of course, arthritis. A recent meta-analysis of all randomized controlled studies for depression yielded some intriguing results.

Has Research Found a Reliable Depression Biomarker in Boys?

A major obstacle in the prevention of depression is the lack of a predictive biomarker in individuals who later develop the disorder. British researchers have shown that the combination of a physiological biomarker—salivary cortisol—and the presence of depressive symptoms might be used to predict the development of major depression in adolescents.

Free Article

Clinical Trials: Show Us the Data [Free Article]

Source: 
Depression
Depression - The Carlat Psychiatry Report (TCPR)

Too often our literature presents an oversimplified picture driven by some agenda, usually commercial. We prescribers, or, more accurately, “research consumers,” need a more complete and accurate description of what’s actually observed in clinical trials.

Deplin: Is it Just Folate by Another Name? [Free Article]

Deplin: Is it Just Folate by Another Name? - The Carlat Psychiatry Report

Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.